-

IFF Pharma Solutions to Showcase Portfolio at Excipient World 2025

Sustainability Expert Will Share Key Insights on Industry-Leading Solutions for Improving Environmental Impact

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) Pharma Solutions, a global leader in polymer innovations, will showcase its sustainable solutions at Excipient World 2025. The team will feature sustainable innovations, controlled-release formulations, and nitrosamine risk mitigation solutions at booth 205 from May 13-14, Gaylord National Resort and Convention Center, National Harbor, Maryland, USA.

“At IFF Pharma Solutions, we believe sustainability is not just a responsibility but an opportunity to innovate and inspire,” said Dr. Anne Adden, global strategic marketing director for sustainability and dietary supplements. “We are committed to creating solutions that not only meet the needs of today but also pave the way for a healthier, more sustainable future. Our team of problem-solvers and experts is redefining what it means to lead in sustainable healthcare.”

Building on over 75 years of industry expertise, IFF Pharma Solutions is ready to present its diverse portfolio of offerings. This includes METHOCEL™ — Pioneering Then, Innovating Now; ETHOCEL™ — Proven Time After Time and POLYOX™ — Versatile Across Complex and Unique Applications. Our experts will also showcase the newly introduced Low Nitrite METHOCEL™ hydroxypropyl methylcellulose (HPMC) and Avicel® PH LN, both developed to reduce nitrosamine risks in pharmaceutical formulations.

Dr. Anne Adden will present “Sustainable by Design: The Future of Excipients” on May 13, from 2:00 to 2:45 p.m. ET, in the Riverview Ballroom, Stage 2. She will discuss how IFF Pharma Solutions incorporates sustainability at every stage of excipient manufacturing, from sourcing materials to packaging.

Visit here to learn more about IFF Pharma Solutions.

Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Contacts

Emily Kaufman
Global Communications Specialist
+1 908.670.5691
emily.kaufman@iff.com

International Flavors & Fragrances

NYSE:IFF

Release Versions

Contacts

Emily Kaufman
Global Communications Specialist
+1 908.670.5691
emily.kaufman@iff.com

More News From International Flavors & Fragrances

IFF Announces Tender Offers for Certain Outstanding Series of Notes

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) announced today the commencement of tender offers to purchase for cash certain of its outstanding series of notes listed in the tables below (collectively, the “Notes”) for an aggregate purchase price, excluding accrued and unpaid interest, of up to $1.8 billion. Pool 1 Tender Offers Pool 1 Maximum Amount: $1.0 billion(1(a)) Title of Security CUSIP/ISIN Principal Amount Outstanding(in millions) Acceptance Priority Level(2) Series Tender Cap(3) U.S. Tre...

IFF Declares Dividend for Second Quarter 2025

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 11, 2025 to shareholders of record as of June 20, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—adva...

IFF Completes Divestiture of Pharma Solutions Business Unit

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its Pharma Solutions business unit to Roquette. “The completion of our Pharma Solutions divestiture represents a significant milestone for IFF as we delivered our targeted net debt to credit-adjusted EBITDA of below 3.0x,” said Erik Fyrwald, IFF CEO. “This is an important step as it allows us to focus on our core strategy – capitalizing on the exciting growth opp...
Back to Newsroom